Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

Bibliographic Details
Main Authors:	Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court, J Paul O’Hare, David McGrane, Tim Holt, Norman Waugh
Format:	Article
Language:	English
Published:	NIHR Journals Library 2018-02-01
Series:	Health Technology Assessment
Online Access:	https://doi.org/10.3310/hta21020-c201802

Similar Items

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation
by: Rhona Johnston, et al.
Published: (2017-01-01)

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
by: Johnston, R, et al.
Published: (2017)

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
by: Odette S Reifsnider, et al.
Published: (2021-08-01)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
by: Victor Sokolov, et al.
Published: (2020-04-01)

Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study
by: Sabrina Kuoni, et al.
Published: (2024-02-01)

Comparison of Extraglycemic effects of Dapagliflozin and Empagliflozin
by: Haroon Aziz, et al.
Published: (2023-06-01)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
by: Hilmi Alnsasra, et al.
Published: (2023-08-01)

Sex-dependent effects of canagliflozin and dapagliflozin on hemostasis in normoglycemic and hyperglycemic mice
by: Natalia Marcińczyk, et al.
Published: (2023-01-01)

Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2023-04-01)

In vivo assessment of the pharmacokinetic interactions between donafenib and dapagliflozin, donafenib and canagliflozin in rats
by: Xueru He, et al.
Published: (2023-06-01)

Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
by: Xingyun Hou, et al.
Published: (2019-05-01)

Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
by: Hao Z, et al.
Published: (2022-07-01)

Divergent electrophysiologic action of dapagliflozin and empagliflozin on ventricular and atrial tachyarrhythmias in isolated rabbit hearts
by: Julian Wolfes, et al.
Published: (2024-02-01)

Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages
by: Yi-Hsuan Lin, et al.
Published: (2019-11-01)

Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
by: A. V. Simanenkova, et al.
Published: (2021-07-01)

Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
by: Dasohm Kim, et al.
Published: (2023-08-01)

Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis
by: Zepeng Shi, et al.
Published: (2022-04-01)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
by: Dong-Dong Wang, et al.
Published: (2022-11-01)

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China.
by: Shuyan Gu, et al.
Published: (2016-01-01)

Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis.
by: Christine Clar, et al.
Published: (2009-07-01)

Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2—Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes
by: Irina Claudia Anton, et al.
Published: (2022-06-01)

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
by: Sjoukje van der Hoek, et al.
Published: (2023-04-01)

Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
by: Jayoung Lim, et al.
Published: (2022-01-01)

The genesis of Clough's poetry
by: McGrane, P, et al.
Published: (2008)

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation
by: N Waugh, et al.
Published: (2010-07-01)

Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study
by: Jaehyun Lim, et al.
Published: (2023-07-01)

Canagliflozin - Beginning of the journey
by: Sunil Kumar Pandey, et al.
Published: (2014-01-01)

Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study
by: Dimitrios Patoulias, et al.
Published: (2022-08-01)

Self-monitoring of blood glucose in type 2 diabetes: systematic review
by: C Clar, et al.
Published: (2010-03-01)

Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
by: N Waugh, et al.
Published: (2010-09-01)

Canagliflozin-Induced Diabetic Ketoacidosis
by: Jessica Turner MSIV, et al.
Published: (2016-08-01)

The bipolarity of attitudes: unfolding the implications of ambivalence
by: McGrane, J
Published: (2018)

The curious case of Queensland and a middle way for senior schooling assessment
by: McGrane, J
Published: (2018)

Stevens’ forgotten crossroads: the divergent measurement traditions in the physical and psychological sciences from the mid-twentieth century
by: McGrane, J
Published: (2015)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
by: Kim HC, et al.
Published: (2023-04-01)

Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
by: Shih-Chieh Shao, et al.
Published: (2019-09-01)

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation
by: N Waugh, et al.
Published: (2013-11-01)

Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial
by: Aldo Ferreira-Hermosillo, et al.
Published: (2020-02-01)

Patient profiling in diabetes and role of canagliflozin
by: Amblee A
Published: (2014-11-01)

Prolonged diabetic ketoacidosis associated with canagliflozin
by: Gordon Sloan, et al.
Published: (2018-06-01)